Back to News
Market Impact: 0.25
MIRA Advances Phase 2a Study Of Ketamir-2 For Chemotherapy-Linked Neuropathy; Stock Up
Source: Nasdaq
Healthcare & Biotech
MIRA Pharmaceuticals reported progress advancing Ketamir-2 toward a Phase 2a trial for chemotherapy-induced peripheral neuropathy. The clinical-stage development milestone is positive for MIRA's pipeline, though no efficacy data, financial impact, or trial timing was disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
MIRA0.60
More News
- Halozyme prices $1.3 billion convertible notes offering
- Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ
- FDA approves Ultragenyx’s Fayuvi for Sanfilippo syndrome Type A
- Why is Xenon Pharmaceuticals stock plunging today?
- Intel and Micron lead our portfolio higher, and J&J's strengthens our case for owning it
- Ultragenyx stock surges 10% on FDA approval for gene therapy